(Q46118161)
Statements
1 reference
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks (English)
1 reference
Mona R Loutfy
1 reference
Joseph Gathe
1 reference
Barbara A da Silva
1 reference
Daniel E Cohen
1 reference
Daniel Podzamczer
1 reference
Rafael Rubio
1 reference
Sara Gibbs
1 reference
Theresa Marsh
1 reference
Christian Naylor
1 reference
Linda Fredrick
1 reference
Barry Bernstein
1 reference
1 April 2009
1 reference
50
1 reference
5
1 reference
474-481
1 reference